


Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Currently amended) A compound of the formula:



Wherein the dashed bond represents a single or double bond;

Aryl signifies a monocyclic heteroaromatic ring selected from the group consisting of thiophene, furan, pyrrole, pyridine, ~~pyrimidine~~pyrimidine, pyridazine, and pyrazine;

$R^1$  is H, OH,  $OC_{1-3}alkyl$ ,  $C_{1-3}alkyl$ ,  $C_{1-3}alkyl$  substituted optionally with OH, or  $OC_{1-3}alkyl$ ;

$R^2$  is H, halogen,  $C_{1-3}alkyl$ ,  $CONR^5R^6$ ,  $S(=O)_mC_{1-3}alkyl$ , or  $C_{1-3}alkyl$  substituted optionally with OH, or  $OC_{1-3}alkyl$ ; with the proviso that if Aryl is thiophene, then  $R^2 \neq H$  or halo, and  $R^1 \neq OH$ ;

$R^3$ ,  $R^4$  are independently H,  $C_{1-3}alkyl$ , or  $C_{1-3}alkyl$  substituted optionally with OH or  $OC_{1-3}alkyl$ ;

$R^5$ ,  $R^6$  are independently H,  $C_{1-3}alkyl$ , or  $C_{2-3}alkyl$  substituted optionally with OH,  $OC_{1-3}alkyl$ , where  $R^5$  and  $R^6$  optionally can be joined together to form a pyrrolidine or piperidine ring which can be either unsubstituted or substituted optionally with  $C_{1-3}alkyl$ ,  $C_{2-3}alkyl$  substituted optionally with OH or  $OC_{1-3}alkyl$ ;

$R^7$ ,  $R^8$  are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine,  $\Delta^3$ -piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from  $C_{1-3}alkyl$ , or  $C_{1-3}alkyl$  substituted optionally with OH,  $OC_{1-3}alkyl$ , or phenyl which can be unsubstituted or substituted optionally with halogen,  $CF_3$ ,  $OC_{1-3}alkyl$ , or  $C_{1-3}alkyl$ , or substituted on nitrogen with  $C_{1-4}alkoxy$  or phenyl which can be unsubstituted or substituted optionally with halogen,  $CF_3$ ,  $OC_{1-3}alkyl$ , or  $C_{1-3}alkyl$ ;


n is 2 to 4;

m is 0, 1 or 2

or a pharmaceutically acceptable salt ~~or solvate~~ thereof.

2 - 4. (Cancelled)

5. (Currently amended) A method for lowering IOP which comprises administering to a person in need thereof, a composition comprising an effective amount of a compound of the formula:



Wherein the dashed bond represents a single or double bond;

Aryl signifies a fused phenyl or monocyclic heteroaromatic ring selected from the group consisting of thiophene, furan, pyrrole, pyridine, ~~pyrimidine~~pyrimidine, pyridazine, and pyrazine;

R¹ is H, OH, OC<sub>1-3</sub>alkyl, C<sub>1-3</sub>alkyl, C<sub>1-3</sub>alkyl substituted optionally with OH, or OC<sub>1-3</sub>alkyl;

R² is H, halogen, C<sub>1-3</sub>alkyl, CONR⁵R⁶, S(=O)<sub>m</sub>C<sub>1-3</sub>alkyl, or C<sub>1-3</sub>alkyl substituted optionally with OH, or OC<sub>1-3</sub>alkyl;

R³, R⁴ are independently H, C<sub>1-3</sub>alkyl, or C<sub>1-3</sub>alkyl substituted optionally with OH or OC<sub>1-3</sub>alkyl;

R⁵, R⁶ are independently H, C<sub>1-3</sub>alkyl, or C<sub>2-3</sub>alkyl substituted optionally with OH, OC<sub>1-3</sub>alkyl, where R⁵ and R⁶ optionally can be joined together to form a pyrrolidine or piperidine ring which can be either unsubstituted or substituted optionally with C<sub>1-3</sub>alkyl, C<sub>2-3</sub>alkyl substituted optionally with OH or OC<sub>1-3</sub>alkyl;


R⁷, R⁸ are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, Δ³-piperidine, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C<sub>1-3</sub>alkyl, C<sub>1-3</sub>alkyl substituted optionally with OH, OC<sub>1-3</sub>alkyl, phenyl which can be unsubstituted or substituted optionally with halogen, CF<sub>3</sub>, OC<sub>1-3</sub>alkyl, or C<sub>1-3</sub>alkyl, or substituted on nitrogen with C<sub>1-4</sub>alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF<sub>3</sub>, OC<sub>1-3</sub>alkyl, or C<sub>1-3</sub>alkyl;

n is 2 to 4;

m is 0, 1 or 2

or a pharmaceutically acceptable salt or solvate thereof.

6. (Currently amended) A method for lowering IOP which comprises administering to a person in need thereof, a composition comprising an effective amount of a compound of the formula:



Wherein the dashed bond represents a single or double bond;

Aryl signifies a fused phenyl or monocyclic heteroaromatic ring selected from the group consisting of thiophene, furan, pyrrole, pyridine, ~~pyrimidine~~pyrimidine, pyridazine, and pyrazine;

R¹ is H, C<sub>1-5</sub>alkyl, C<sub>3-5</sub>alkenyl, an aromatic ring selected from the group consisting of phenyl, thienyl, pyridyl, and imidazolyl which is either unsubstituted or substituted optionally with OH, OC<sub>1-3</sub>alkyl, S(=O)<sub>m</sub>C<sub>1-3</sub>alkyl, halogen, or CF<sub>3</sub>; or C<sub>2-5</sub>alkyl substituted optionally with OH, OC<sub>1-3</sub>alkyl, S(=O)<sub>m</sub>C<sub>1-3</sub>alkyl or an aromatic ring selected from the group consisting of phenyl, thienyl, pyridyl, and imidazolyl, which is either unsubstituted or substituted optionally with OH, OC<sub>1-3</sub>alkyl, S(=O)<sub>m</sub>C<sub>1-3</sub>alkyl, halogen, CF<sub>3</sub>, S(=O)<sub>2</sub> NR<sup>5</sup>R<sup>6</sup>; or C<sub>3-5</sub>alkenyl substituted optionally with OH, OC<sub>1-3</sub>alkyl, or S(=O)<sub>m</sub>C<sub>1-3</sub>alkyl;

R² is H, halogen, C<sub>1-3</sub>alkyl, S(=O)<sub>m</sub>C<sub>1-3</sub>alkyl, S(=O)<sub>2</sub> NR<sup>5</sup>R<sup>6</sup>, or C<sub>1-3</sub>alkyl substituted optionally with OH, or OC<sub>1-3</sub>alkyl;

R³ & R⁴ are independently H, C<sub>1-3</sub>alkyl, or C<sub>1-3</sub>alkyl substituted optionally with OH or OC<sub>1-3</sub>alkyl;

R⁵, R⁶ are independently H, C<sub>1-3</sub>alkyl, or C<sub>2-3</sub>alkyl substituted optionally with OH, OC<sub>1-3</sub>alkyl, where R⁵ and R⁶ optionally can be joined together to form a pyrrolidine or piperidine ring which can be either unsubstituted or substituted optionally with C<sub>1-3</sub>alkyl, C<sub>2-3</sub>alkyl substituted optionally with OH or OC<sub>1-3</sub>alkyl;

R⁷, R⁸ are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, Δ³-piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or

substituted on carbon with one or more substituents optionally selected from C<sub>1-3</sub>alkyl, C<sub>1-3</sub>alkyl substituted optionally with OH, OC<sub>1-3</sub>alkyl, or phenyl which can be unsubstituted or substituted optionally with halogen, CF<sub>3</sub>, OC<sub>1-3</sub>alkyl, or C<sub>1-3</sub>alkyl, or substituted on nitrogen with C<sub>1-4</sub>alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF<sub>3</sub>, OC<sub>1-3</sub>alkyl, or C<sub>1-3</sub>alkyl;

n is 2 to 4;


m is 0, 1 or 2

or a pharmaceutically acceptable salt or solvate thereof.

7. (Cancelled)

8. (Cancelled)

9. (Currently Amended) A method for improving blood flow to the optic nerve head and the retina which comprises administering to a person in need thereof, a composition comprising an effective amount of a compound of the formula:



Wherein the dashed bond represents a single or double bond;

Aryl signifies a monocyclic heteroaromatic ring selected from the group consisting of thiophene, furan, pyrrole, pyridine, ~~pyrimidine~~pyrimidine, pyridazine, and pyrazine;

R¹ is H, OH, OC<sub>1-3</sub>alkyl, C<sub>1-3</sub>alkyl, C<sub>1-3</sub>alkyl substituted optionally with OH, or OC<sub>1-3</sub>alkyl;

R² is H, halogen, C<sub>1-3</sub>alkyl, CONR⁵R⁶, S(=O)<sub>m</sub>C<sub>1-3</sub>alkyl, or C<sub>1-3</sub>alkyl substituted optionally with OH, or OC<sub>1-3</sub>alkyl; with the proviso that if Aryl is thiophene, then R² ≠ H or halo, and R¹ ≠ OH;

R³, R⁴ are independently H, C<sub>1-3</sub>alkyl, or C<sub>1-3</sub>alkyl substituted optionally with OH or OC<sub>1-3</sub>alkyl;

R⁵, R⁶ are independently H, C<sub>1-3</sub>alkyl, or C<sub>2-3</sub>alkyl substituted optionally with OH, OC<sub>1-3</sub>alkyl, where R⁵ and R⁶ optionally can be joined together to form a pyrrolidine or piperidine

ring which can be either unsubstituted or substituted optionally with C<sub>1-3</sub>alkyl, C<sub>2-3</sub>alkyl substituted optionally with OH or OC<sub>1-3</sub>alkyl;


R<sup>7</sup>, R<sup>8</sup> are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, Δ<sup>3</sup>-piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C<sub>1-3</sub>alkyl, or C<sub>1-3</sub>alkyl substituted optionally with OH, OC<sub>1-3</sub>alkyl, or phenyl which can be unsubstituted or substituted optionally with halogen, CF<sub>3</sub>, OC<sub>1-3</sub>alkyl, or C<sub>1-3</sub>alkyl, or substituted on nitrogen with C<sub>1-4</sub>alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF<sub>3</sub>, OC<sub>1-3</sub>alkyl, or C<sub>1-3</sub>alkyl;

n is 2 to 4;

m is 0, 1 or 2

or a pharmaceutically acceptable salt or solvate thereof.

10. (Currently Amended) A method for improving blood flow to the optic nerve head and the retina which comprises administering to a person in need thereof, a composition comprising an effective amount of a compound of the formula:



Wherein the dashed bond represents a single or double bond;

Aryl signifies a fused phenyl or monocyclic heteroaromatic ring selected from the group consisting of thiophene, furan, pyrrole, pyridine, ~~pyrimidine~~pyrimidine, pyridazine, and pyrazine;

R¹ is H, C<sub>1-5</sub>alkyl, C<sub>3-5</sub>alkenyl, an aromatic ring selected from the group consisting of phenyl, thienyl, pyridyl, and imidazolyl which is either unsubstituted or substituted optionally with OH, OC<sub>1-3</sub>alkyl, S(=O)<sub>m</sub>C<sub>1-3</sub>alkyl, halogen, or CF<sub>3</sub>; or C<sub>2-5</sub>alkyl substituted optionally with OH, OC<sub>1-3</sub>alkyl, S(=O)<sub>m</sub>C<sub>1-3</sub>alkyl or an aromatic ring selected from the group consisting of phenyl, thienyl, pyridyl, and imidazolyl, which is either unsubstituted or substituted

optionally with OH, OC<sub>1-3</sub>alkyl, S(=O)<sub>m</sub>C<sub>1-3</sub>alkyl, halogen, CF<sub>3</sub>, S(=O)<sub>2</sub> NR<sup>5</sup>R<sup>6</sup>; or C<sub>3-5</sub>alkenyl substituted optionally with OH, OC<sub>1-3</sub>alkyl, or S(=O)<sub>m</sub>C<sub>1-3</sub>alkyl;

R<sup>2</sup> is H, halogen, C<sub>1-3</sub>alkyl, S(=O)<sub>m</sub>C<sub>1-3</sub>alkyl, S(=O)<sub>2</sub> NR<sup>5</sup>R<sup>6</sup>, or C<sub>1-3</sub>alkyl substituted optionally with OH, or OC<sub>1-3</sub>alkyl;

R<sup>3</sup> & R<sup>4</sup> are independently H, C<sub>1-3</sub>alkyl, or C<sub>1-3</sub>alkyl substituted optionally with OH or OC<sub>1-3</sub>alkyl;

R<sup>5</sup>, R<sup>6</sup> are independently H, C<sub>1-3</sub>alkyl, or C<sub>2-3</sub>alkyl substituted optionally with OH, OC<sub>1-3</sub>alkyl, where R<sup>5</sup> and R<sup>6</sup> optionally can be joined together to form a pyrrolidine or piperidine ring which can be either unsubstituted or substituted optionally with C<sub>1-3</sub>alkyl, C<sub>2-3</sub>alkyl substituted optionally with OH or OC<sub>1-3</sub>alkyl;

R<sup>7</sup>, R<sup>8</sup> are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, Δ<sup>3</sup>-piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C<sub>1-3</sub>alkyl, C<sub>1-3</sub>alkyl substituted optionally with OH, OC<sub>1-3</sub>alkyl, or phenyl which can be unsubstituted or substituted optionally with halogen, CF<sub>3</sub>, OC<sub>1-3</sub>alkyl, or C<sub>1-3</sub>alkyl, or substituted on nitrogen with C<sub>1-4</sub>alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF<sub>3</sub>, OC<sub>1-3</sub>alkyl, or C<sub>1-3</sub>alkyl;

n is 2 to 4;

m is 0, 1 or 2

or a pharmaceutically acceptable salt or solvate thereof.


11. (Cancelled)

12. (Cancelled)

13. (Currently amended) A method for treating retinal diseases selected from the group consisting of glaucoma, age related macular degeneration (ARMD), optic neuritis, ischemic disorders, diabetic retinopathy, and retinal edema which comprises administering to a person in need thereof, a composition comprising an effective amount of a compound of the formula:



comprises administering to a person in need thereof, a composition comprising an effective amount of a compound of the formula:



Wherein the dashed bond represents a single or double bond;

Aryl signifies a fused phenyl or monocyclic heteroaromatic ring selected from the group consisting of thiophene, furan, pyrrole, pyridine, ~~pyrimidine~~ pyrimidine, pyridazine, and pyrazine;

R<sup>1</sup> is H, C<sub>1-5</sub>alkyl, C<sub>3-5</sub>alkenyl, an aromatic ring selected from the group consisting of phenyl, thienyl, pyridyl, and imidazolyl which is either unsubstituted or substituted optionally with OH, OC<sub>1-3</sub>alkyl, S(=O)<sub>m</sub>C<sub>1-3</sub>alkyl, halogen, or CF<sub>3</sub>; or C<sub>2-5</sub>alkyl substituted optionally with OH, OC<sub>1-3</sub>alkyl, S(=O)<sub>m</sub>C<sub>1-3</sub>alkyl or an aromatic ring selected from the group consisting of phenyl, thienyl, pyridyl, and imidazolyl, which is either unsubstituted or substituted optionally with OH, OC<sub>1-3</sub>alkyl, S(=O)<sub>m</sub>C<sub>1-3</sub>alkyl, halogen, CF<sub>3</sub>, S(=O)<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>; or C<sub>3-5</sub>alkenyl substituted optionally with OH, OC<sub>1-3</sub>alkyl, or S(=O)<sub>m</sub>C<sub>1-3</sub>alkyl;

R<sup>2</sup> is H, halogen, C<sub>1-3</sub>alkyl, S(=O)<sub>m</sub>C<sub>1-3</sub>alkyl, S(=O)<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>, or C<sub>1-3</sub>alkyl substituted optionally with OH, or OC<sub>1-3</sub>alkyl;

R<sup>3</sup> & R<sup>4</sup> are independently H, C<sub>1-3</sub>alkyl, or C<sub>1-3</sub>alkyl substituted optionally with OH or OC<sub>1-3</sub>alkyl;

R<sup>5</sup>, R<sup>6</sup> are independently H, C<sub>1-3</sub>alkyl, or C<sub>2-3</sub>alkyl substituted optionally with OH, OC<sub>1-3</sub>alkyl, where R<sup>5</sup> and R<sup>6</sup> optionally can be joined together to form a pyrrolidine or piperidine ring which can be either unsubstituted or substituted optionally with C<sub>1-3</sub>alkyl, C<sub>2-3</sub>alkyl substituted optionally with OH or OC<sub>1-3</sub>alkyl;

R<sup>7</sup>, R<sup>8</sup> are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, Δ<sup>3</sup>-piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C<sub>1-3</sub>alkyl, C<sub>1-3</sub>alkyl substituted optionally with OH, OC<sub>1-3</sub>alkyl, or phenyl which can be unsubstituted or substituted optionally with halogen, CF<sub>3</sub>, OC<sub>1-3</sub>alkyl, or C<sub>1-3</sub>alkyl, or



substituted on nitrogen with C<sub>1-4</sub>alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF<sub>3</sub>, OC<sub>1-3</sub>alkyl, or C<sub>1-3</sub>alkyl;


n is 2 to 4;

m is 0, 1 or 2

or a pharmaceutically acceptable salt or solvate thereof.

15 – 38. (Cancelled)

39. (Currently Amended) A method for treating persons suffering from a sleeping disorder, depression, schizophrenia, anxiety, circadian rhythm disorders, and centrally and peripherally mediated hypertension, which comprises, administering a composition comprising a pharmaceutically effective amount of a compound of the formula:



Wherein the dashed bond represents a single or double bond;

Aryl signifies a monocyclic heteroaromatic ring selected from the group consisting of thiophene, furan, pyrrole, pyridine, ~~pyrimidine~~pyrimidine, pyridazine, and pyrazine;

R¹ is H, OH, OC<sub>1-3</sub>alkyl, C<sub>1-3</sub>alkyl, C<sub>1-3</sub>alkyl substituted optionally with OH, or OC<sub>1-3</sub>alkyl;

R² is H, halogen, C<sub>1-3</sub>alkyl, CONR⁵R⁶, S(=O)<sub>m</sub>C<sub>1-3</sub>alkyl, or C<sub>1-3</sub>alkyl substituted optionally with OH, or OC<sub>1-3</sub>alkyl; with the proviso that if Aryl is thiophene, then R² ≠ H or halo, and R¹ ≠ OH;

R³, R⁴ are independently H, C<sub>1-3</sub>alkyl, or C<sub>1-3</sub>alkyl substituted optionally with OH or OC<sub>1-3</sub>alkyl;

R⁵, R⁶ are independently H, C<sub>1-3</sub>alkyl, or C<sub>2-3</sub>alkyl substituted optionally with OH, OC<sub>1-3</sub>alkyl, where R⁵ and R⁶ optionally can be joined together to form a pyrrolidine or piperidine ring which can be either unsubstituted or substituted optionally with C<sub>1-3</sub>alkyl, C<sub>2-3</sub>alkyl substituted optionally with OH or OC<sub>1-3</sub>alkyl;


$R^7$ ,  $R^8$  are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine,  $\Delta^3$ -piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from  $C_{1-3}$ alkyl, or  $C_{1-3}$ alkyl substituted optionally with OH,  $OC_{1-3}$ alkyl, or phenyl which can be unsubstituted or substituted optionally with halogen,  $CF_3$ ,  $OC_{1-3}$ alkyl, or  $C_{1-3}$ alkyl, or substituted on nitrogen with  $C_{1-4}$ alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen,  $CF_3$ ,  $OC_{1-3}$ alkyl, or  $C_{1-3}$ alkyl;

n is 2 to 4;

m is 0, 1 or 2

or a pharmaceutically acceptable salt or solvate thereof.

40. (Currently amended) A method for treating persons suffering from a sleeping disorder, depression, schizophrenia, anxiety, obsessive compulsive disorder, circadian rhythm disorders, and centrally and peripherally mediated hypertension which comprises, administering a composition comprising a pharmaceutically effective amount of a compound of the formula:



Wherein the dashed bond represents a single or double bond;

Aryl signifies a fused phenyl or monocyclic heteroaromatic ring selected from the group consisting of thiophene, furan, pyrrole, pyridine, ~~pyrimidine~~pyrimidine, pyridazine, and pyrazine;

$R^1$  is H,  $C_{1-5}$ alkyl,  $C_{3-5}$ alkenyl, an aromatic ring selected from the group consisting of phenyl, thienyl, pyridyl, and imidazolyl which is either unsubstituted or substituted optionally with OH,  $OC_{1-3}$ alkyl,  $S(=O)_mC_{1-3}$ alkyl, halogen, or  $CF_3$ ; or  $C_{2-5}$ alkyl substituted optionally with OH,  $OC_{1-3}$ alkyl,  $S(=O)_mC_{1-3}$ alkyl or an aromatic ring selected from the group consisting of phenyl, thienyl, pyridyl, and imidazolyl, which is either unsubstituted or substituted

optionally with OH, OC<sub>1-3</sub>alkyl, S(=O)<sub>m</sub>C<sub>1-3</sub>alkyl, halogen, CF<sub>3</sub>, S(=O)<sub>2</sub> NR<sup>5</sup>R<sup>6</sup>; or C<sub>3-5</sub>alkenyl substituted optionally with OH, OC<sub>1-3</sub>alkyl, or S(=O)<sub>m</sub>C<sub>1-3</sub>alkyl;

R<sup>2</sup> is H, halogen, C<sub>1-3</sub>alkyl, S(=O)<sub>m</sub>C<sub>1-3</sub>alkyl, S(=O)<sub>2</sub> NR<sup>5</sup>R<sup>6</sup>, or C<sub>1-3</sub>alkyl substituted optionally with OH, or OC<sub>1-3</sub>alkyl;

R<sup>3</sup> & R<sup>4</sup> are independently H, C<sub>1-3</sub>alkyl, or C<sub>1-3</sub>alkyl substituted optionally with OH or OC<sub>1-3</sub>alkyl;

R<sup>5</sup>, R<sup>6</sup> are independently H, C<sub>1-3</sub>alkyl, or C<sub>2-3</sub>alkyl substituted optionally with OH, OC<sub>1-3</sub>alkyl, where R<sup>5</sup> and R<sup>6</sup> optionally can be joined together to form a pyrrolidine or piperidine ring which can be either unsubstituted or substituted optionally with C<sub>1-3</sub>alkyl, C<sub>2-3</sub>alkyl substituted optionally with OH or OC<sub>1-3</sub>alkyl;

R<sup>7</sup>, R<sup>8</sup> are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, Δ<sup>3</sup>-piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C<sub>1-3</sub>alkyl, C<sub>1-3</sub>alkyl substituted optionally with OH, OC<sub>1-3</sub>alkyl, or phenyl which can be unsubstituted or substituted optionally with halogen, CF<sub>3</sub>, OC<sub>1-3</sub>alkyl, or C<sub>1-3</sub>alkyl, or substituted on nitrogen with C<sub>1-4</sub>alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF<sub>3</sub>, OC<sub>1-3</sub>alkyl, or C<sub>1-3</sub>alkyl;

n is 2 to 4;


m is 0, 1 or 2

or a pharmaceutically acceptable salt or solvate thereof.

41. (Cancelled)

42. (Cancelled)

43. (Currently amended) A composition comprising a pharmaceutically effective amount of a compound of the formula:



Wherein the dashed bond represents a single or double bond;

Aryl signifies a monocyclic heteroaromatic ring selected from the group consisting of thiophene, furan, pyrrole, pyridine, ~~pyrimidine~~pyrimidine, pyridazine, and pyrazine;

$R^1$  is H, OH,  $OC_{1-3}alkyl$ ,  $C_{1-3}alkyl$ ,  $C_{1-3}alkyl$  substituted optionally with OH, or  $OC_{1-3}alkyl$ ;

$R^2$  is H, halogen,  $C_{1-3}alkyl$ ,  $CONR^5R^6$ ,  $S(=O)_mC_{1-3}alkyl$ , or  $C_{1-3}alkyl$  substituted optionally with OH, or  $OC_{1-3}alkyl$ ; with the proviso that if Aryl is thiophene, then  $R^2 \neq H$  or halo, and  $R^1 \neq OH$ ;

$R^3$ ,  $R^4$  are independently H,  $C_{1-3}alkyl$ , or  $C_{1-3}alkyl$  substituted optionally with OH or  $OC_{1-3}alkyl$ ;

$R^5$ ,  $R^6$  are independently H,  $C_{1-3}alkyl$ , or  $C_{2-3}alkyl$  substituted optionally with OH,  $OC_{1-3}alkyl$ , where  $R^5$  and  $R^6$  optionally can be joined together to form a pyrrolidine or piperidine ring which can be either unsubstituted or substituted optionally with  $C_{1-3}alkyl$ ,  $C_{2-3}alkyl$  substituted optionally with OH or  $OC_{1-3}alkyl$ ;


$R^7$ ,  $R^8$  are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine,  $\Delta^3$ -piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from  $C_{1-3}alkyl$ , or  $C_{1-3}alkyl$  substituted optionally with OH,  $OC_{1-3}alkyl$ , or phenyl which can be unsubstituted or substituted optionally with halogen,  $CF_3$ ,  $OC_{1-3}alkyl$ , or  $C_{1-3}alkyl$ , or substituted on nitrogen with  $C_{1-4}alkoxy$  or phenyl which can be unsubstituted or substituted optionally with halogen,  $CF_3$ ,  $OC_{1-3}alkyl$ , or  $C_{1-3}alkyl$ ;

n is 2 to 4;

m is 0, 1 or 2

or a pharmaceutically acceptable salt or ~~solvate~~ thereof in a pharmaceutically acceptable carrier.

44. (Currently amended) A composition comprising a pharmaceutically effective amount of a compound of the formula:



Wherein the dashed bond represents a single or double bond;

Aryl signifies a fused phenyl or monocyclic heteroaromatic ring selected from the group consisting of thiophene, furan, pyrrole, pyridine, ~~pyrimidine~~pyrimidine, pyridazine, and pyrazine;

R<sup>1</sup> is H, C<sub>1-5</sub>alkyl, C<sub>3-5</sub>alkenyl, an aromatic ring selected from the group consisting of phenyl, thienyl, pyridyl, and imidazolyl which is either unsubstituted or substituted optionally with OH, OC<sub>1-3</sub>alkyl, S(=O)<sub>m</sub>C<sub>1-3</sub>alkyl, halogen, or CF<sub>3</sub>; or C<sub>2-5</sub>alkyl substituted optionally with OH, OC<sub>1-3</sub>alkyl, S(=O)<sub>m</sub>C<sub>1-3</sub>alkyl or an aromatic ring selected from the group consisting of phenyl, thienyl, pyridyl, and imidazolyl, which is either unsubstituted or substituted optionally with OH, OC<sub>1-3</sub>alkyl, S(=O)<sub>m</sub>C<sub>1-3</sub>alkyl, halogen, CF<sub>3</sub>, S(=O)<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>; or C<sub>3-5</sub>alkenyl substituted optionally with OH, OC<sub>1-3</sub>alkyl, or S(=O)<sub>m</sub>C<sub>1-3</sub>alkyl;

R<sup>2</sup> is H, halogen, C<sub>1-3</sub>alkyl, S(=O)<sub>m</sub>C<sub>1-3</sub>alkyl, S(=O)<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>, or C<sub>1-3</sub>alkyl substituted optionally with OH, or OC<sub>1-3</sub>alkyl;

R<sup>3</sup> & R<sup>4</sup> are independently H, C<sub>1-3</sub>alkyl, or C<sub>1-3</sub>alkyl substituted optionally with OH or OC<sub>1-3</sub>alkyl;

R<sup>5</sup>, R<sup>6</sup> are independently H, C<sub>1-3</sub>alkyl, or C<sub>2-3</sub>alkyl substituted optionally with OH, OC<sub>1-3</sub>alkyl, where R<sup>5</sup> and R<sup>6</sup> optionally can be joined together to form a pyrrolidine or piperidine ring which can be either unsubstituted or substituted optionally with C<sub>1-3</sub>alkyl, C<sub>2-3</sub>alkyl substituted optionally with OH or OC<sub>1-3</sub>alkyl;

R<sup>7</sup>, R<sup>8</sup> are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, Δ<sup>3</sup>-piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C<sub>1-3</sub>alkyl, C<sub>1-3</sub>alkyl substituted optionally with OH, OC<sub>1-3</sub>alkyl, or phenyl which can be unsubstituted or substituted optionally with halogen, CF<sub>3</sub>, OC<sub>1-3</sub>alkyl, or C<sub>1-3</sub>alkyl, or substituted on nitrogen with C<sub>1-4</sub>alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF<sub>3</sub>, OC<sub>1-3</sub>alkyl, or C<sub>1-3</sub>alkyl;

n is 2 to 4;

m is 0, 1 or 2

or a pharmaceutically acceptable salt or solvate thereof in a pharmaceutically acceptable carrier.

45. (Cancelled)

46. (Cancelled)

47. (Original) The Compound of Claim 1 selected from the group consisting of:

6-Chloro-2-[4-[4-(2*H*-benzimidazo-2-oxo-1-yl)piperidin-1-yl]butyl]-2*H*-thieno[3,2-*e*]-1,2-thiazine  
1,1-dioxide;

6-Chloro-2-[4-(4-phenylpiperazin-1-yl)butyl]-2*H*-thieno[3,2-*e*]-1,2-thiazine 1,1-dioxide;

6-Chloro-2-[4-[4-(2-fluorophenyl)piperazin-1-yl]butyl]-2*H*-thieno[3,2-*e*]-1,2-thiazine 1,1-dioxide;

6-Chloro-2-[3-[4-(3-trifluoromethylphenyl)piperazin-1-yl]propyl]-2*H*-thieno[3,2-*e*]-1,2-thiazine  
1,1-dioxide;

6-Chloro-2-[3-[4-(2*H*-benzimidazol-2-oxo)piperidin-1-yl]propyl]-2*H*-thieno[3,2-*e*]-1,2-thiazine  
1,1-dioxide.

48. (Cancelled)

49. (Cancelled)